Document:

Form of Statement of Confidentiality, Non-Disclosure and Non-Compete Agreement

 EXHIBIT 10.4 
 FORM OF STATEMENT OF CONFIDENTIALITY, NON-DISCLOSURE 
 AND NON-COMPETE AGREEMENT BETWEEN ALCIS-CA
AND 
 OUR EMPLOYEES, CONSULTANTS AND OTHER THIRD-PARTY CONTRACTORS 
 ALCiS HEALTH, INC. 
 CONFIDENTIAL INFORMATION AND INVENTIONS AGREEMENT

 As an employee of ALCiS Health, Inc, its subsidiary or its affiliate (together, the “Company”), and in consideration of the
compensation now and hereafter paid to me, I, the undersigned, agree to the following: 
 1. Maintaining Confidential
Information 
 a. Company Information. I agree at all times during the term of my employment and thereafter to hold in strictest
confidence, and not to use, except for the benefit of the Company, or to disclose to any person, firm or corporation without written authorization of the Board of Directors of the Company, any trade secrets, confidential knowledge, data or other
proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans, financial information or
other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees. 
 b. Former Employer
Information. I agree that I will not, during my employment with the Company, improperly use or disclose any proprietary information or trade secrets of my former or concurrent employers or companies, if any, and that I will not bring onto the
premises of the Company any unpublished document or any property belonging to my former or concurrent employers or companies, if any, unless consented to in writing by said employers or companies. 
 c. Third Party Information. I recognize that the Company has received and in the future will receive from third parties their confidential or
proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes. I agree that I owe the Company and such third parties, during the term of my
employment and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except as necessary in carrying out my work for the Company consistent
with the Company’s agreement with such third party) or to use it for the benefit of anyone other than for the Company or such third party (consistent with the Company’s agreement with such third party) without the express written
authorization of the Board of Directors of the Company. 
 2. Retaining and Assigning Inventions and Original Works

 a. Inventions and Original Works Retained by Me. I have attached hereto, as Exhibit A, a list describing all inventions,
original works of authorship, developments, improvements, and trade secrets which were made by me prior to my employment with the Company, which belong to me, which relate to the Company’s proposed business and products, and which are not
assigned to the Company; or, if no such list is attached, I represent that there are no such inventions. 
 b. Inventions and Original
Works Assigned to the Company. I agree that I will promptly 

 make full written disclosure to the Company, will hold in trust for the sole right and benefit of the Company, and will
assign to the Company all my right, title, and interest in and to any and all inventions, original works of authorship, developments, improvements or trade secrets which I may solely or jointly conceive or develop or reduce to practice, or cause to
be conceived or developed or reduced to practice, during the period of time I am in the employ of the Company. I recognize, however, that Section 2870 of the California Labor Code (as set forth in Exhibit B attached hereto) exempts from
this provision any invention as to which I can prove the following: 
 (i) It was developed entirely on my own time; and 
 (ii) No equipment, supplies, facilities or trade secrets of the Company were used in its development; and 
 (iii) It either 
 (aa) does not relate, at
the time the invention was conceived or reduced to practice, to the Company’s business or to the Company’s actual or demonstrably anticipated research and development; or 
 (bb) does not result from any work performed by me for the Company. 
 I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by copyright are “works made for hire,” as
that term is defined in the United States Copyright Act (17 USCA, Section 101). 
 c. Maintenance of Records. I agree to keep and
maintain adequate and current written records of all inventions and original works of authorship made by me (solely or jointly with others) during the term of my employment with the Company. The records will be in the form of notes, sketches,
drawings, and any other format that may be specified by the Company. The records will be available to and remain the sole property of the Company at all times. 
 d. Inventions Assigned to the United States. I agree to assign to the United States government all my right, title, and interest in and to any and all inventions, original works of authorship, developments,
improvements or trade secrets whenever such full title is required to be in the United States by a contract between the Company and the United States or any of its agencies. 
 e. Obtaining Letters Patent and Copyright Registrations. I agree that my obligation to assist the Company to obtain United States or foreign
letters patent and copyright registrations covering inventions and original works of authorship assigned hereunder to the Company shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate for
time actually spent by me at the Company’s request on such assistance. If the Company is unable because of my mental or physical incapacity or for any other reason to secure my signature to apply for or to pursue any application for any United
States or foreign letters patent or copyright registrations covering inventions or original works of authorship assigned to the Company as above, then I hereby irrevocably designate and appoint the Company and its duly authorized officers and agents
as my agent and attorney in fact, to act for and in my behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations
thereon with the same legal force and effect as if executed by me. I hereby waive and quitclaim to the Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any patents or copyrights, resulting
from any such application for letters patent or copyright registrations assigned hereunder to the Company. 

 f. Exception to Assignments. I understand that the provisions of this Agreement requiring
assignment to the Company do not apply to any invention which qualifies fully under the provisions of Section 2870 of the California Labor Code, a copy of which is attached hereto as Exhibit B. I will advise the Company promptly in writing
of any inventions, original works of authorship, developments, improvements or trade secrets that I believe meet the criteria in Subparagraphs 2b(i), (ii), and (iii) above; and I will at that time provide to the Company in writing all evidence
necessary to substantiate that belief. I understand that the Company will keep in confidence and will not disclose to third parties without my consent any confidential information disclosed in writing to the Company relating to inventions that
qualify fully under the provisions of Section 2870 of the California Labor Code. 
 3. Conflicting Employment. I agree that, during the term of
my employment with the Company, I will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of my employment,
nor will I engage in any other activities that conflict with my obligations to the Company. 
 4. Returning Company Documents. I agree that, at the
time of leaving the employ of the Company, I will deliver to the Company (and will not keep in my possession or deliver to anyone else) any and all devices, records, data, notes, reports, proposals, lists, correspondence, specifications, drawings,
blueprints, sketches, materials, equipment, other documents or property, or reproductions of any aforementioned items belonging to the Company, its successors or assigns. In the event of the termination of my employment, I agree to sign and deliver
the “Termination Certification” attached hereto as Exhibit C. 
 5. Representations. I agree to execute any proper oath or verify any
proper document required to carry out the terms of this Agreement. I represent that my performance of all the terms of this Agreement will not breach any agreement to keep in confidence proprietary information acquired by me in confidence or in
trust prior to my employment by the Company. I have not entered into, and I agree I will not enter into, any oral or written agreement in conflict herewith. 
 6. General Provisions 
 a. Governing Law. This Agreement will be governed by the laws of the State of California. 
 b. Entire Agreement. This
Agreement sets forth the entire agreement and understanding between the Company and me relating to the subject matter herein and merges all prior discussions between us. No modification of or amendment to this Agreement, nor any waiver of any rights
under this agreement, will be effective unless in writing signed by the party to be charged. Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. 
 c. Severability. If one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full
force and effect. 
 d. Successors and Assigns. This Agreement will be binding upon my heirs, executors, administrators and other
legal representatives and will be for the benefit of the Company, its successors, and its assigns. 
  

			
	Date:                     	 	
		 	  

		 	Name:

 EXHIBIT A 
 LIST OF PRIOR INVENTIONS 
 AND ORIGINAL WORKS OF AUTHORSHIP 
  

					
	 Title
	 	 Date
	 	 Identifying Number
 or Brief Description

		 		 	
		 		 	
		 		 	

 Name of Employee:
                                        
             

 EXHIBIT B 
 CALIFORNIA LABOR CODE SECTION 2870 
 EMPLOYMENT AGREEMENTS; ASSIGNMENT OF RIGHTS 
 “(a) Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or
her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer’s equipment, supplies, facilities, or trade secret information except for those inventions that either:

 (1) Relate at the time of conception or reduction to practice of the invention to the employer’s business, or actual or demonstrably
anticipated research or development of the employer. 
 (2) Result from any work performed by the employee for the employer. 
 (b) To the extent a provision in an employment agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned
under subdivision (a), the provision is against the public policy of this state and is unenforceable.” 

 EXHIBIT C 
 ALCiS HEALTH, INC. 
 TERMINATION CERTIFICATION 
 This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals, lists, correspondence,
specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any aforementioned items belonging to ALCiS Health, Inc., its subsidiaries, affiliates, successors or assigns (together, the
“Company”). 
 I further certify that I have complied with all the terms of the Company’s Confidential Information and Inventions Agreement
signed by me, including the reporting of any inventions and original works of authorship (as defined therein), conceived or made by me (solely or jointly with others) covered by that agreement. 
 I further agree that, in compliance with the Employee Confidential Information and Inventions Agreement, I will preserve as confidential all trade secrets, confidential
knowledge, data or other proprietary information relating to products, processes, know-how, designs, formulas, developmental or experimental work, computer programs, data bases, other original works of authorship, customer lists, business plans,
financial information or other subject matter pertaining to any business of the Company or any of its clients, consultants or licensees. 
  

			
	Date:                     	 	
		 	  

		 	Name:

 Nondisclosure and Non-Circumvention Agreement 
 THIS AGREEMENT is made this      day of             , 2006 (the
“Effective Date”), by and between ALCIS HEALTH, INC. (“Company”) and
                                        
                                        
     (“Recipient”). 
 The undersigned intend to engage in discussions concerning the Company’s actual or proposed
technology, technology acquisitions (including but not limited to acquisition of patented anti-inflammatory and liposomal delivery system technologies), designs, concepts, innovations, products and/or services of Company and plans, studies or
projections with respect thereto, all of which are non-public and unannounced, relating to the Company’s current and planned products (hereinafter collectively referred to as the “Company Business”); 
 Whereas Recipient desires to obtain certain information for the sole purpose of entering into a business or investment relationship with the Company, understanding that
the Contact Sources are important and valuable to the Company’s current and future business ventures, and whereas Recipient has no intent to partner with such Contact Sources in a manner which is not in Company’s best interests;

 Whereas, because such discussions may require disclosure of information considered confidential and proprietary by Company, including the identity of the
current owner of the patented anti-inflammatory and liposomal delivery system technologies, and because Company will participate in such discussions only upon the understanding set forth herein, Recipient agrees with Company that Recipient will
maintain the secrecy of such information as set forth below; 
 For good and valuable consideration, which is hereby
acknowledged as received, the parties agree as follows: 
 (1) For the purposes of establishing and enforcing this Agreement, the parties do hereby agree upon
the following definitions as used herein: 
 “Representative Relationship” shall be interpreted to mean any agent, licensee,
employment or independent contractor relationship entered into for the purpose of providing or receiving funds, license rights, technology, products and/or services from or to the Contact Source. 
 “Contact Source” shall be interpreted to mean any person, partnership, corporation or other legal entity, including but not limited to those
persons, partnerships, corporations or other legal entities with whom Company has a current working relationship. 
 (2) For each Contact Source disclosed by
Company, the term (“Term”) of this Agreement shall commence on the Effective Date and continue until three (3) years after the date Company’s contractual relationship with such Contact Source terminates. The Term for any Contact
Source shall extend to and continue during any Company/Contact Source contract renewal periods. During the Term, Recipient does hereby agree that neither Recipient nor Recipient’s employees, agents, consultants, corporations, divisions,
subsidiaries or partnerships or any other person, group or entity associated with Recipient, will make contact with, attempt to deal with or enter into (i) any competitive contract with such Contact Source, (ii) any contract or
relationship with such Contact Source which is harmful to Company’s interests or (iii) any Representative Relationship with any Contact Source introduced to Recipient by agents or principals of Company, without Company’s prior written
consent to such contract or relationship, which may be withheld in Company’s reasonable discretion. 
 (3) Recipient does hereby agree to keep
confidential and not to disclose the name, address, telephone, and fax number(s) of any Contact Source introduced to Recipient by agents or principals of Company, as well as any other confidential information that Recipient receives during the Term.
Recipient does further agree and acknowledge that such information, including the identity and means of contact of any Contact Source introduced to Recipient by agents or principals of Company, is the proprietary information, trade secret and
property of Company and shall so remain for the Term. Upon termination of discussions or upon the written request of Company, Recipient will return forthwith all written or descriptive matter of every kind including but not limited to models,
prototypes, notes, documents, etc. which contain such Confidential Information. Recipient agrees to hold each item of Confidential Information received in confidence until three (3) years after the expiration or termination of this Agreement.

 (4) “Confidential Information”, as used herein, shall mean all information, noted as “Confidential”
as set forth below, which is disclosed or otherwise provided by Company, or any representations thereof which relates to or refers to Company information, business strategy, and technology. Confidential Information shall not include such
information: 
  

	 	a.	which was in the public domain prior to any such disclosure by Company; 

  

	 	b.	which, after disclosure by Company, comes into the public domain through no fault of the Recipient; 

  

	 	c.	which is disclosed to Recipient by a third party lawfully and with a legitimate right to disclose; or 

  

	 	d.	which was in the legitimate possession of Recipient prior to such disclosure as evidenced by Recipient’s written records. 

 Recipient will hold all Confidential Information in trust and confidence; and will not at any time, without the prior written consent of Company, disclose Confidential
Information to any person other than an employee of Recipient who is bound to maintain the confidentiality of such Confidential Information and who has an actual need to know such Confidential Information in order to advance the purposes of this
Agreement and the discussions pursuant hereto; and, will not use or employ any Confidential Information in connection with any business or commercial activity which is separate from or does not involve Company. Notwithstanding the definition of
Company Information, and notwithstanding the public filing status of the anti-inflammatory and liposomal delivery system patents, Recipient will not discuss the anti-inflammatory and liposomal delivery system patents or their availability for
acquisition with any party other than the Company for a period of 3 years from execution of this agreement. 
 (5) In the event that any litigation is
commenced between the Recipient and Company relative to this Agreement or the rights and duties of the Recipient or Company under this Agreement, the prevailing party in any such litigation shall be entitled, in addition to such relief as may be
granted, to the actual sum expended for attorneys’ fees and court costs as determined by the court in such litigation. Should any part or provision of this Agreement be deemed invalid or unenforceable, it is the intention of the parties hereto
that the remaining portions of the Agreement shall remain in full force and effect. This Agreement shall be binding upon and inure to the benefit of the successors, heirs, assignees, agents and principals of the parties hereto. This Agreement shall
not be modified or amended except in writing and signed by the parties hereto and specifically referring to this Agreement. This Agreement shall be construed under the laws of California, United States of America and any dispute arising out of this
Agreement shall be adjudicated in a court in the State of California, United States of America. 
 IN WITNESS WHEREOF, this Agreement is executed in the City
of San Jose, County of Santa Clara, pursuant to the Laws of the State of California on the date first hereinabove written. 
  

					
	ALCIS HEALTH, INC.	 		 	 Recipient:

	560 S. Winchester Blvd., Fifth Floor, San Jose, CA 95120	 		 	
			
	Signature _____________________________________	 		 	Signature ____________________________________
			
	Name ________________________________________	 		 	Name _______________________________________
	Title _________________________________________	 		 	Title ________________________________________
			
	Date:             , 2006	 		 	                    , 2006Form of Subscription Agreement

 EXHIBIT 10.5 
 FORM OF SUBSCRIPTION AGREEMENT RELATING TO OFFERING CONSUMMATED 
 MARCH 31, 2006 FOR THE SALE
OF COMMON STOCK AND WARRANTS 
 ALCiS HEALTH, INC. 
  

 SUBSCRIPTION MATERIALS 
  

 • INSTRUCTIONS TO
SUBSCRIBERS 
 • SUBSCRIPTION AGREEMENT 
 March 2006 

 INSTRUCTIONS TO SUBSCRIBERS 
 IF, AFTER YOU HAVE CAREFULLY REVIEWED THE CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM DATED MARCH 2006 (THE “MEMORANDUM”) OF ALCiS HEALTH, INC.
(THE “COMPANY”), YOU DECIDE TO PURCHASE UNITS (AS DESCRIBED IN THE MEMORANDUM), PLEASE CAREFULLY OBSERVE THE INSTRUCTIONS BELOW. THE INFORMATION REQUESTED IN THESE SUBSCRIPTION PAPERS IS NECESSARY TO ENSURE EXEMPTION FROM REGISTRATION
UNDER SECTION 4(2) AND REGULATION D OF THE SECURITIES ACT OF 1933, AS AMENDED. SUCH INFORMATION IS CONFIDENTIAL AND WILL NOT BE REVIEWED BY ANYONE OTHER THAN THE COMPANY AND ITS COUNSEL. ALL SUBSCRIPTION PAPERS MUST BE COMPLETED, CORRECTLY SIGNED
AND DATED, OR THEY MAY NOT BE ACCEPTED. 
 CAPITALIZED TERMS USED BUT NOT DEFINED HEREIN SHALL HAVE THE MEANINGS ASCRIBED TO THEM IN THE MEMORANDUM.

 The minimum suitability standards are set forth in the Memorandum and the Qualified Purchaser Questionnaire contained as part of this subscription
package. The minimum subscription amount is $50,000. The Company, in its sole discretion, may accept offers to purchase lesser amounts. 
 DO NOT SIGN THE
SUBSCRIPTION AGREEMENT UNLESS YOU CAN MAKE ALL THE REPRESENTATIONS CONTAINED THEREIN AND IN THE ATTACHED QUALIFIED PURCHASER QUESTIONNAIRE. 
 1. Subscription Agreement. 
 Every subscriber must deliver a dated, completed and executed Subscription
Agreement. Please read the Subscription Agreement carefully and (a) fill in the amount you wish to subscribe for, (b) insert your residence address if you are an individual or your business address if you are a Company, corporation, trust
or other entity, (c) indicate the exact name in which you wish your Units to be held, and (d) otherwise complete the Subscription Agreement. 
 If
the subscribers are joint purchasers, and are not husband and wife who have the same principal residence, each subscriber must complete a separate Subscription Agreement. In any event, each joint purchaser (whether or not husband and wife) must sign
the signature page. When signing the Subscription Agreement, insert the social security number(s) of the subscriber(s) or tax identification number, as applicable, below the signature line. 
 2. Qualified Purchaser Information 
 Every subscriber must complete the Qualified Purchaser information in Sections IV, V, and VI. If there are joint purchasers and such purchasers are husband and wife who have the same principal residence, only one purchaser need complete the
Qualified Purchaser information in Sections IV, V, and VI and the requested information should be furnished with respect to such purchaser. Each joint purchaser who is not a spouse with the same principal residence must separately complete the
Qualified Purchaser information in Sections IV, V, and VI. 

 3. Purchaser Representative Questionnaire 
 If you have used a financial advisor to assist you in evaluating an investment in the Units, such financial advisor must deliver a dated, completed, and executed
Purchaser Representative Questionnaire. 
 4. Payment. 
 The undersigned shall pay the undersigned’s entire subscription amount specified in Section VI, by wire transfer. To obtain wire instructions, please contact Mark
Lemma, ALCiS Chief Financial Officer, at (408) 236-7530. 
 5. Special Instructions for Trustees and
Agents. 
 Trustees, agents or other persons acting in a representative capacity are required to indicate on the completed Subscription Agreement the
name of the person or entity for whom he is acting as trustee or agent. 
 6. Delivery of Subscription
Package. 
 Investors should deliver the executed subscription documents and payment for the offered securities to ALCiS Health, Inc., 560 South
Winchester Blvd., Fifth Floor, San Jose, California 95128, Attn: Mark Lemma. 
 7. Acceptance. 
 Upon your subscription being accepted, you will receive shortly thereafter a copy of your Subscription Agreement countersigned by the Company. 
 PLEASE KEEP THESE SUBSCRIPTION PAPERS CONFIDENTIAL AND DISCUSS THEM ONLY WITH YOUR SPOUSE AND PROFESSIONAL ADVISORS. IF YOU DECIDE NOT TO INVEST IN THE COMPANY, PLEASE
RETURN THESE SUBSCRIPTION PAPERS AND ALL OTHER DOCUMENTS FURNISHED TO YOU. PLEASE DO NOT DISCARD OR DESTROY THESE SUBSCRIPTION PAPERS OR OTHER SUCH PAPERS YOURSELF. NEITHER THESE SUBSCRIPTION PAPERS NOR SUCH OTHER DOCUMENTS MAY BE REPRODUCED OR
DISTRIBUTED IN ANY MANNER. 
 FOR RESIDENTS OF ALL STATES 
 IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THE UNITS HAVE NOT BEEN RECOMMENDED OR APPROVED
BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 THE UNITS ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

 ALCiS Health, Inc. 
 $3,500,000 COMMON STOCK WITH WARRANTS OFFERING 
 $1,500,000 Minimum Offering 
 $2.00 PER UNIT 
 $50,000 MINIMUM
SUBSCRIPTION 
 SUBSCRIPTION AGREEMENT 
 This document should be read and responded to in its entirety. (Please Type or Print in Ink) 
  

			
	Full Name:	  	
	 Of Subscriber:
	  	 ______________________________________________________________

	 Of Joint Subscriber (if any):
	  	 ______________________________________________________________

		
	Subscription Amount ($):	  	 ______________________________________________________________

		
	Email Address:	  	 ______________________________________________________________

		
	Residence Address:	  	
	 Of Subscriber:
	  	 ______________________________________________________________

		  	 ______________________________________________________________

		  	 ______________________________________________________________

	 Of Joint Subscriber (if any):
	  	 ______________________________________________________________

		  	 ______________________________________________________________

		  	 ______________________________________________________________

	Mailing Address (if different):	  	
	 Of Subscriber:
	  	 ______________________________________________________________

		  	 ______________________________________________________________

	 Of Joint Subscriber (if any):
	  	 ______________________________________________________________

		  	 ______________________________________________________________

	Telephone Number:	  	
	 Of Subscriber:
	  	 ______________________________________________________________

	 Of Joint Subscriber (if any):
	  	 ______________________________________________________________

		
	Taxpayer ID, FED I.D. #:	  	 ______________________________________________________________

 GENERAL INSTRUCTIONS FOR SUBSCRIBERS 
 IF, AFTER YOU HAVE CAREFULLY REVIEWED THE PRIVATE PLACEMENT MEMORANDUM AND ALL OTHER MATERIALS PROVIDED TO YOU BY ALCIS HEALTH, INC. (THE
“COMPANY”), YOU WISH TO SUBSCRIBE TO PURCHASE UNITS OF THE COMPANY (THE “UNITS”), PLEASE FOLLOW CAREFULLY THE INSTRUCTIONS BELOW. 
 THE INFORMATION REQUESTED IN THIS SUBSCRIPTION AGREEMENT IS REQUIRED IN CONNECTION WITH THE COMPANY’S INTENDED RELIANCE UPON CERTAIN EXEMPTIONS FROM THE REGISTRATION AND QUALIFICATION REQUIREMENTS OF FEDERAL AND
STATE SECURITIES LAWS. SUBSCRIPTION AGREEMENTS THAT ARE MISSING REQUESTED INFORMATION AND/OR SIGNATURES CANNOT AND WILL NOT BE ACCEPTED UNLESS AND UNTIL SUCH INFORMATION AND/OR SIGNATURES ARE PROVIDED. SUCH INFORMATION IS CONFIDENTIAL AND WILL NOT
BE REVIEWED BY ANYONE OTHER THAN THE COMPANY AND ITS ADVISORS. 
 ALL SUBSCRIBERS: 
 Carefully read this Subscription Agreement. Sections I—III and VI contain certain important notices, understandings as to certain matters, subscriber
representations and warranties, and registration information. These sections pertain to ALL SUBSCRIBERS. Section IV requests information regarding the financial condition and experience of prospective investors who are individuals
(“Individual Subscribers” or “Prospective Investors”) and should be completed only by Individual Subscribers. Section V requests information regarding the financial condition and experience of prospective investors
that are entities (“Entity Subscribers” or “Prospective Investors”) and should be completed only by Entity Subscribers. 
 One copy of the Subscription Agreement must be filled out completely and signed by each subscriber. All parties involved in reviewing and evaluating your Subscription Agreement will be relying on the
representations and warranties you make and on the information you supply. Any subscriber may be required to furnish additional information to enable the Company to determine whether the subscriber is a qualified investor. 
 JOINT SUBSCRIBERS: 
 In the case of joint
subscribers, where such subscribers are husband and wife or relatives and have the same principal residence, only the subscriber primarily responsible for evaluating the investment and making the decision to invest must complete Section IV of this
Agreement. In the case of joint subscribers who are not husband and wife or relatives or do not have the same principal residence, each joint subscriber must complete a Subscription Agreement. Joint subscribers must take title to the Units jointly
and shall supply instructions to the Company as to the form of ownership desired. 
 ENTITY SUBSCRIBERS: 
 The Company may request that each Entity Subscriber submit with its Subscription Agreement the form of certificate corresponding to its form of
organization together with a copy of its most recent financial statements. The Company reserves the right to require, at its sole discretion, an opinion of legal counsel from any Entity Subscriber. 
 When used herein, the terms “I”, “you”, “your” and “the undersigned” shall mean the Prospective Investor
executing this Agreement below. 

 I. IMPORTANT NOTICES CONCERNING THE OFFERING 
 This offering relates to the private offer and sale (the “Offering”) of up to 1,750,000 shares of ALCiS Health, Inc. Common Stock plus warrants, at a price of $2.00 per unit. The common stock (the
“Shares” or “Common Stock”) and the warrants (the “Warrants”) together shall be referred to as the “Unit” or “Units.” 
 Each Share of Common Stock shall be accompanied by 20% Warrant coverage exercisable at $2.00 per Share and 20% Warrant coverage exercisable at $3.75 per Share. For example, 5 Units shall consist of (i) 5 Shares
of Common Stock, (ii) an accompanying Warrant exercisable for 1 additional Share at $2.00 per Share and (iii) an accompanying Warrant exercisable for 1 additional Share at $3.75 per Share. 
 In addition to the Warrants described above, investments of $1,000,000 or more (made in one payment and titled under one investor name) shall also receive additional 20%
Warrant coverage exercisable at $4.75 per Share. For example, an investment of $1,000,000 shall purchase 500,000 Units, which shall consist of (i) 500,000 Shares of Common Stock, (ii) an accompanying Warrant exercisable for 100,000
additional Shares at $2.00 per Share (iii) an accompanying Warrant exercisable for 100,000 additional Shares at $3.75 per Share and (iv) an accompanying Warrant exercisable for 100,000 additional Shares at $4.75 per Share. 
 The minimum investment is fifty thousand dollars ($50,000), but the Company, in its discretion, may accept subscriptions in smaller amounts. The total offering for this
Offering, if fully subscribed, is three million five hundred dollars ($3,500,000). The minimum consideration required to be raised under the Offering is one million five hundred thousand dollars ($1,500,000). 
 All proceeds from sales of the Units sold under this Offering subscription agreement shall initially be placed in escrow with Wilmington Trust
Company. Such funds shall only be released upon the occurrence of both the following events: (i) The Company’s achievement of a “Qualified Financing” shall be defined as any offering by which the Company secures gross proceeds of
one million five hundred thousand dollars ($1,500,000) or more, the achievement of which is confirmed in writing to the escrow agent by both Delta and the Company and (ii) Emerging Delta has approved and executed all merger documentation.
Subscriber herein appoints Emerging Delta as its agent to confirm to the escrow agent whether or not a Qualified Financing is achieved, and the escrow agent shall be permitted to rely on Delta’s confirmation of the same. No Commissions shall be
payable until the merger is complete, and will be made contemporaneously with funds being released from escrow. 
 THE COMMON STOCK,
WARRANTS AND UNITS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE “BLUE SKY” OR SECURITIES LAWS. THE COMMON STOCK, WARRANTS AND UNITS CANNOT BE SOLD, TRANSFERRED,
ASSIGNED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH APPLICABLE FEDERAL AND STATE SECURITIES LAWS AND WILL NOT BE TRANSFERRED OF RECORD EXCEPT IN COMPLIANCE WITH SAID LAWS. THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

 THIS OFFERING INVOLVES CERTAIN MATERIAL RISKS. IN MAKING AN 

 INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING
THE MERITS AND RISKS INVOLVED. THERE CURRENTLY IS NO TRADING MARKET FOR THE SECURITIES OF THE COMPANY, AND NONE IS EXPECTED TO DEVELOP FOLLOWING THIS OFFERING. 
 PROSPECTIVE INVESTORS MUST BE ABLE TO BEAR THE ECONOMIC RISK OF THE INVESTMENT FOR AN INDEFINITE PERIOD OF TIME, BECAUSE THE SECURITIES
CANNOT BE SOLD OR TRANSFERRED EXCEPT AS PERMITTED BY THE SECURITIES ACT, AND APPLICABLE PROVISIONS OF STATE SECURITIES LAWS. IF, AS A RESULT OF SOME CHANGE OF CIRCUMSTANCES ARISING FROM AN EVENT NOT NOW IN CONTEMPLATION, OR FOR ANY OTHER REASON, AN
INVESTOR WISHES TO TRANSFER HIS OR HER SECURITIES, SUCH INVESTOR MAY FIND NO MARKET FOR THOSE SECURITIES. 
 PRIOR TO THE
ISSUANCE OF ANY SECURITIES, PROSPECTIVE INVESTORS SHALL BE GIVEN THE OPPORTUNITY TO ASK QUESTIONS AND RECEIVE ANSWERS CONCERNING ANY ASPECT OF THE INVESTMENT, AND TO OBTAIN ANY ADDITIONAL INFORMATION, TO THE EXTENT THE COMPANY POSSESSES SUCH
INFORMATION OR CAN ACQUIRE IT WITHOUT UNREASONABLE EFFORT OR EXPENSE. 
 PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE THE
CONTENTS OF THIS SUBSCRIPTION AGREEMENT AS LEGAL, TAX OR INVESTMENT ADVICE. EACH INVESTOR SHOULD CONSULT HIS OR HER OWN LEGAL COUNSEL, ACCOUNTANT OR BUSINESS ADVISOR AS TO LEGAL, TAX AND RELATED MATTERS CONCERNING ANY POSSIBLE INVESTMENT IN THE
SECURITIES OFFERED HEREBY. THE DELIVERY OF THIS SUBSCRIPTION AGREEMENT AT ANY TIME DOES NOT IMPLY THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE HEREOF. 
 II. AGREEMENTS AND UNDERSTANDINGS 
 I agree and
understand as follows: 
 A. Except as may be provided under state securities laws, this Subscription Agreement is irrevocable; provided,
however, that the execution and delivery of this Subscription Agreement will not constitute an agreement between the Company and me until this Subscription Agreement is accepted by the Company. I understand that the Company may request any other
information, whether or not specifically called for in this Subscription Agreement, which it deems desirable in evaluating my subscription. Furthermore, I understand that the Company has the right to reject my subscription with or without cause, for
any or no reason. 
 B. Although I realize that the Company will make a good faith effort to sell the Units without undue delay, I understand
that some time may pass after my execution and submission of this Subscription Agreement before any decision to accept or reject my subscription is made. I understand that a delay in deciding whether to accept or reject my subscription, even if such
delay involves not including my subscription in a given closing or in any closing, can in no way be interpreted as limiting the discretion of the Company to accept or reject my subscription. 

 C. I will make such representations and warranties and furnish such additional information as to my
investment experience and financial position as the Company may reasonably request, and if there should be any material change in the information set forth herein prior to the closing of the sale of Units to me, I will immediately furnish such
revised or corrected information to the Company. 
 D. I understand that in the event that my Subscription Agreement is not accepted for
whatever reason, my subscription funds will be returned to me without interest or escrow fee. 
 E. I recognize that in accepting my
subscription to purchase Units, the Company will rely on the accuracy and completeness of my statements, representations and warranties set forth herein. I hereby agree to defend, to indemnify and to hold harmless the Company and each of its
officers, directors, principals, agents, successors, assigns and affiliates of the Company, from and against any and all loss, damage, liability or expense, including reasonable attorneys’ fees and costs, which they or any of them may incur or
become liable for by reason of, or in any way connected with, any misrepresentation or omission of relevant information, whether negligent or intentional, made by me in this Subscription Agreement, any breach of my warranties or my failure to
perform any of my covenants or agreements set forth in the Subscription Agreement, or arising out of any sale or distribution by me of any Common Stock or Units in violation of the Securities Act, or any other applicable securities or “Blue
Sky” laws. 
 III. REPRESENTATIONS AND WARRANTIES 
 I represent and warrant to the Company that: 
 A. I have been given full access to information appropriate to
my determination of whether to invest in the Company, and I am familiar with the terms and provisions thereof. I have also received and reviewed the Private Placement Memorandum prepared in connection with the proposed offering by the Company of the
Units, which summarizes the proposed rights and privileges of the Units and describes the issued and outstanding equity securities of the Company. I acknowledge that I am aware of the risk factors relating to this investment, which should be
considered when determining whether to invest in the Units. 
 B. I have further had an opportunity to meet with principals of the Company,
to ask questions, and discuss issues relevant to my determination of whether to invest in the Units. 
 C. I have full legal capacity to
enter into this Subscription Agreement and, if not an individual, have duly authorized the execution of this Subscription Agreement in accordance with my constitutive documents. 
 D. I have carefully reviewed the merits and risks of, and other considerations relating to, investment in the Company. 
 E. I have read and understood the notices set forth in Section I, and I understand that the transfer of the Units is subject to various restrictions;
that, as the Units have not been registered under the Securities Act, or under the securities laws of any state, the Units cannot be sold unless registered under said Act and qualified under said state laws or are exempt from registration or
qualification thereunder; that the Company will not record the sale or other transfer of any Common Stock, Warrants or Units without compliance with said securities laws; and that I must bear the economic risk of ownership of Units for an indefinite
period of time. I shall not sell, assign, transfer or otherwise dispose of all or any part of my Units or my interests therein except in compliance with applicable federal and state securities laws. 

 F. I understand that my investment in the Company is not liquid. I have adequate means of providing for
my current needs and personal contingencies and I have no need for liquidity in this investment. 
 G. Except for the Private Placement
Memorandum and any other information that my advisors or I may have requested and received directly from the Company, neither my advisors nor I have been furnished any other offering material or literature upon which I have relied in connection with
my determination of whether or not to purchase Units. 
 H. I have been advised that I and my advisors, if any, would have an opportunity to
review all the pertinent facts, to ask questions, and to obtain any additional information, to the extent possessed or obtainable without unreasonable effort and expense, regarding the Company, its key employees, its business, the offering of the
Units, the risks of investment in the Company and any other matters relating to any of the above, and any additional information necessary to verify the accuracy of any representation or information provided above. The Company has supplied all
material requested, if any, and has given complete and satisfactory answers to all inquiries, if any, that my advisors and I have put to it concerning the matters listed above. 
 I. All financial and other data that I have supplied in this Subscription Agreement is true, accurate, and complete and fairly reflects my financial
condition and investment experience to the best of my knowledge and belief. 
 J. I have been advised to consult with my own attorney
regarding legal matters concerning an investment in the Company and regarding tax and other financial consequences of investing in the Company. I understand that the information provided to me by the Company in connection with my purchase of the
Units does not constitute legal, investment, tax or other advice. 
 K. I am acquiring the Units for my own account, as principal, for
investment and not with a view to or for sale in connection with any distribution of such Units or any interest therein. 
 L. I understand
that an investment in the Company will be subject to substantial risks and uncertainties, not all of which are described in this Subscription Agreement. 
 M. I understand any information I have received which contains statements of anticipated or expected financial results and projected financial statement information, including internally-prepared projected revenues,
projected cash flow statements, and projected balance sheets for the Company, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to
various risks and uncertainties. I understand and further acknowledge that those forward-looking statements depend on certain assumptions about the Company, its market, the competition it faces, and its revenue model, and I acknowledge that those
assumptions may prove to be inaccurate and, as a result, the projected financial statement information and related information may not prove to be accurate statements of the actual financial results or the financial condition of the Company. I have
had an opportunity to discuss those projected financial statements, and the assumptions underlying such projected financial statements, with the Company’s management. 

 IV. FINANCIAL CONDITION AND EXPERIENCE OF INDIVIDUAL SUBSCRIBERS: 
 (ENTITY SUBSCRIBERS SHOULD SKIP THIS SECTION IV AND COMPLETE SECTION V INSTEAD) 
 I further represent and warrant to the Company, as follows: 
 A. 
 I am an “accredited
investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act. My qualification is based on the following (each “accredited investor” must initial the appropriate item or items): 
              1. I had an individual income (exclusive of the income of my spouse) in excess of
$200,000 for each of the two most recent years, or joint income with my spouse in excess of $300,000 in each of those years, and reasonably expect the same income level for the current year; or 
              2. As of the date of this Subscription Agreement, I (either individually or with my
spouse) have a net worth in excess of $1,000,000; or 
              3. I am an officer or
director of the Company. 
 B. 
  

	            	4. I am not an “accredited investor” (initial, if appropriate). 

 V. AUTHORITY AND FINANCIAL CONDITION OF ENTITY SUBSCRIBERS: 
 THE REQUESTED FINANCIAL INFORMATION SHOULD BE FURNISHED ONLY WITH RESPECT TO THE ENTITY SUBSCRIBER, AND NOT WITH RESPECT TO ANY OF THE OWNERS OF THE
BENEFICIAL INTERESTS THEREIN, EXCEPT AS INDICATED. 
 GRANTOR TRUST SUBSCRIBERS: IF THE SUBSCRIBER IS A GRANTOR TRUST, THAT IS, A
TRUST AMENDABLE AND REVOCABLE BY THE GRANTOR AT ANY TIME, PLEASE COMPLETE THIS SECTION V WITH RESPECT TO THE TRUST AND ITS ASSETS ALONE. PLEASE ALSO COMPLETE SECTION IV WITH RESPECT TO THE GRANTOR INCLUDING THE ASSETS HELD IN THE TRUST. 

A. REPRESENTATIONS AND WARRANTIES  
 The undersigned represents and warrants to the Company as follows: 
 (1) The undersigned has been duly formed and is validly
existing in good standing under the laws of the state in which it was founded with full power and authority to enter into the transactions contemplated by this Subscription Agreement. 
 (2) The execution of this Agreement has been duly and validly authorized, and, when delivered on behalf of the undersigned, will constitute a valid,
binding and enforceable agreement and obligation of the undersigned. 
 (3) The undersigned has not been formed, reformed or recapitalized
for the specific purpose of purchasing Units. 
 (4) The undersigned acknowledges that all representations, warranties, agreements and
notices set forth in Sections I - III apply to the undersigned and acknowledges having read and understood them. Where appropriate in the context, the words “I” and “me” have been read to mean “the undersigned.”

 B. FINANCIAL POSITION AND EXPERIENCE  
  

	
	 Type of entity: _____________________________________________________________

	
	 Date of Organization: __________________________________________________________

	
	 State of Organization: __________________________________________________________

	
	 Number of equity owners (partners, beneficiaries, etc.): ________________________________

 If one or more of these equity owners owns individually or collectively more than fifty percent
(50%) of the equity interest of the subscriber and is (are) also purchasing Units, please identify such equity owner(s): 
 _________________________________________________________________________________________________________________________________________________ 
 _________________________________________________________________________________________________________________________________________________ 

 Indicate whether the Subscriber is any of the following types of entity (initial any applicable
category): 
 (i)              A bank or savings and loan institution,
whether acting in its individual or fiduciary capacity. 
 (ii)
             An insurance company. 
 (iii)
             An investment company registered under the Investment Company Act of 1940. 
 (iv)              A business development company as defined in the Investment Company Act of 1940. 
 (v)              A private business development company as defined in the Investment
Advisors Act of 1940. 
 (vi)              A Small Business Investment
Company licensed by the U.S. Small Business Administration. 
 (vii)             An employee benefit plan within the meaning of Title I of the Employment Retirement Income Security Act of 1974 (ERISA), if the investment decision with
respect to this investment is made by a plan fiduciary which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000. 

(viii)              An employee benefit plan established and maintained by a state
or state agency, if the plan has total assets in excess of $5,000,000. 
 (ix)
             Any tax exempt organization as defined in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust or partnership not
formed for specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000. 
 (x)
             An entity of which the owners are (1) institutional investors described in the foregoing subparagraphs (i)-(ix), (2) “Individuals” who meet certain
suitability standards1/, or (3) or a combination of both. 
 (xi)
             A trust with total assets in excess of $5,000,000, not formed 
  

	1/	For purposes of paragraph (x) above, “Individuals” shall mean one or more natural persons, each of whom: (A) has a net worth individually, or
jointly with his or her spouse, of more than $1,000,000; or (B) has had individual annual gross income from all sources in excess of $200,000, or joint income with a spouse in excess of $300,000, in each of the two most recent years and a
reasonable expectation of reaching the same income level in the current year; or (C) is an Officer or Director of the Company; or (D) is a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; or
(E) in most cases, may reasonably be deemed by the Company to have such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the prospective investment.

 for the specific purpose of acquiring the securities, whose purchase is directed by a person with
knowledge and experience in financial matters, capable of evaluating the merits and risks of the prospective investment. 
 The net worth of
the undersigned, as set forth in greater detail on the financial statements submitted herewith (if the Company so requests) is: 
 $                                 
 The undersigned’s principal activities are: 
 _________________________________________________________________________________________________________________________________________________ 
 _________________________________________________________________________________________________________________________________________________ 
 _________________________________________________________________________________________________________________________________________________ 
 C. INVESTMENT EVALUATION 
 Please certify the truth of the following statement by initialing where
indicated: 
 The individuals authorizing this investment on behalf of Subscriber have such knowledge and experience in financial and business
matters so as to be capable of evaluating the merits and risks of an investment in the Company. 
                      (Initials) 

 VI. ALL SUBSCRIBERS 
 A. Title. The Subscriber, or joint subscribers, wish(es) to take title to the Units as follows: 
  

	
	             Individual, as a Single Person
	
	             Individual, Subject to Community Property Rights of Spouse
	
	             Individual, as Separate Property
	
	             Husband and Wife, as Community Property
	
	             As Tenants-In-Common
	
	             As Joint Tenants with Rights of Survivorship
	
	             Other (e.g., corporation, partnership, trustee or custodian)

 The exact spelling of the name(s) to be on the title: 
 Name:
                                        
                                        

 B. Number of Units. The Subscriber wish(es) to subscribe to the following number of Units of the Company: 
                              Units, at $2.00 per Unit 
 For investments of under $1,000,000 (made in one payment and titled under one investor name), each Unit shall consist of (i) one share of Common Stock plus
(ii) 20% Warrant coverage exercisable at $2.00 per Share and (iii) 20% Warrant coverage exercisable at $3.75 per Share. For example, 5 Units shall consist of (i) 5 Shares of Common Stock, (ii) an accompanying Warrant exercisable
for 1 additional Share at $2.00 per Share and (iii) an accompanying Warrant exercisable for 1 additional Share at $3.75 per Share. 
 For investments of
$1,000,000 or more, each Unit shall consist of (i) one share of Common Stock plus (ii) 20% Warrant coverage exercisable at $2.00 per Share, plus (iii) 20% Warrant coverage exercisable at $3.75 per Share, and (iv) 20% Warrant
coverage exercisable at $4.75 per Share. For example, an investment of $1,000,000 shall purchase 500,000 Units, which shall consist of (i) 500,000 Shares of Common Stock, (ii) an accompanying Warrant exercisable for 100,000 additional
Shares at $2.00 per Share (iii) an accompanying Warrant exercisable for 100,000 additional Shares at $3.75 per Share and (iv) an accompanying Warrant exercisable for 100,000 additional Shares at $4.75 per Share. 
 C. Payment Methods. Payment may be made (i) by wire to: Wilmington Trust Company, ABA No. 031-100-092, Alcis Inc Escrow, Account
No. 074055-000, or (ii) by check, payable to “Wilmington Trust Company, as Escrow Agent for Alcis Health, Inc.” and sent to Wilmington Trust Company, Attn: Scott Huff, 1100 North Market Street, Mail Code 1625, Wilmington DE,
19890. 
 D. Legend. The Subscriber acknowledges that a legend to the following effect will appear upon the Common Stock: 

THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR 

 INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN
THE ABSENCE OF SUCH REGISTRATION OR UNLESS THE COMPANY RECEIVES AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT STATING THAT SUCH SALE OR TRANSFER IS EXEMPT FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. COPIES OF THE
AGREEMENT COVERING THE PURCHASE OF THESE SHARES AND RESTRICTING THEIR TRANSFER MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF THE CORPORATION AT THE PRINCIPAL EXECUTIVE OFFICES OF
THE CORPORATION. 
 The Subscriber agrees promptly to deliver the certificate representing Subscriber’s Common Stock to the Company if
and when the Company, in its discretion, decides to recall such certificate and reissue the same bearing a new or different legend or legends reflecting appropriately any requirements of the exemptions from the state and federal securities laws
pursuant to which Common Stock have been sold to Subscriber. 
 E. Following acceptance of this Subscription Agreement, Subscriber will
receive stock certificates, warrants and other relevant documentation within 90 days of completion of the Merger. 
 VII. COVENANTS AND AGREEMENTS

 For purposes of Sections A and C below, Shareholder shall mean Subscriber and any person to whom Subscriber transferred the Shares who
prior to such transfer delivered to the Company a written agreement agreeing to be bound by this Section XII. 
 A. Registration Rights.

 Shareholder shall have the following registration rights until March 31, 2008: 
  

	 	1.	If at any time ALCiS decides to register any of its securities pursuant to an underwritten offering for its own account or for the account of others, ALCiS shall promptly send to
each Shareholder written notice of ALCiS’ intention to file a registration statement and of such Shareholder rights hereunder and, if within twenty days after receipt of such notice, such Shareholder shall so request in writing, ALCiS shall
include in such registration statement all or any part of the Shareholder’s securities in ALCiS that such Shareholder requests to be registered, subject to the priorities set forth herein. 

  

	 	2.	If the registration for which ALCiS gives notice is a public offering involving an underwriting, ALCiS will so advise Shareholder as part of the above-described written notice. In
such event, if the managing underwriter(s) advise ALCiS in writing, that in their reasonable good faith opinion, marketing or other factors dictate that a limitation on the number of common shares which may be included in the registration statement
(which may include a total “cut-back” of all registrable securities) is necessary to facilitate and not adversely affect the proposed offering, then ALCiS shall include in such registration: (a) first, all securities that ALCiS
proposes to sell for its own account, and (b) second, the securities requested to be registered by Shareholder and other holders of securities entitled to participate in the registration, as of the date hereof, drawn from them pro rata based on
the number of shares held by them. 

  

	 	3.	If an offering in connection with which Shareholder is entitled to registration under this section of this Agreement is an underwritten offering, then each Shareholder whose
registrable securities are included in such registration statement shall, unless otherwise agreed by ALCiS, immediately 

 prior to registration, convert the investor’s securities to common shares of ALCiS, and offer and
sell such registrable securities in such underwritten offering using the same underwriter or underwriters and on the same terms and conditions as other shares included in such underwritten offering. 
 B. Anti-Dilution Protection 
 The Common
Stock and shares obtainable on exercise of the Warrants shall be subject to full ratchet adjustment to prevent dilution in the event that ALCiS or Delta issues additional common shares or any right or option to purchase common shares or other
security convertible into or exchangeable for common shares at a purchase price less than the purchase price (after any proportional adjustments for stock splits, stock dividends, recapitalizations, and the like) of the common shares. For these
purposes, the Common Stock has a deemed value of $2.00 per share, and with respect to the Common Stock, as an example, if a subsequent round of financing were to be consummated at $1.00 per share, Common Stock shareholders would have the right to
convert their shares at the $1.00 price, thereby doubling the number of shares they are entitled to receive. For these purposes, the Warrants have a stated exercise price, and if a subsequent round of the Common Stock financing is to consummated at
a reduced price, the Warrant exercise price is reduced by the same dollar value, e.g. if $2.00 per share Common Stock is subsequently sold at $1.00 per share, a Warrant with a $4.75 exercise price shall be adjusted to carry a $3.75 exercise price, a
Warrant with a $3.75 exercise price shall be adjusted to carry a $2.75 exercise price and a Warrant with a $2.00 exercise price shall be adjusted to carry a $1.00 exercise price. Antidilution protection shall not apply to (i) shares issued
pursuant to ALCiS’ stock option plan, not to exceed 1,300,000 shares or any greater amount approved by a vote of the Common Stock, voting as a separate class (as adjusted for any stock split, stock dividend or recapitalization or like event of
ALCiS), (ii) placement fees relating to the sale of Common Stock, (iii) shares given in conjunction with the purchase of technology from the patent holder/manufacturer, (iv) trading values of the shares in a public market, or
(v) waiver of such anti-dilution protection as approved by a two-thirds vote of Common Stock shareholders, voting as a separate class (as adjusted for any stock split, stock dividend or recapitalization or like event of ALCiS). Anti-Dilution
protection shall terminate on the earlier of (i) six (6) months following the effective date of a registration statement filed by the Company, post merger, (ii) upon trading of the shares in a public market or
(iii) March 31, 2009. 
 C. Miscellaneous. 
 This Section VII may be amended by a Shareholder and the Company as to such Shareholder or by the Company and those shareholders (including Shareholder) then owning a majority of the shares of Common Stock purchased
in this Offering as to all shareholders. This Agreement is governed by California law and constitutes the entire agreement and understanding of Subscriber and the Company concerning its subject matter, superseding all prior and concurrent agreements
and understandings concerning its subject matter. 
 SIGNATURES ON FOLLOWING PAGE(S) 

 IN WITNESS WHEREOF, the undersigned has executed this Subscription Agreement as of the date indicated
below. 
 INDIVIDUAL SUBSCRIBERS: 
 Dated:                     , 2006 

	
	  

	
	  

	 (Print Name Here)

 IF THE SUBSCRIBER HAS INDICATED THAT HE OR SHE WILL HOLD THE UNITS AS A JOINT TENANTS, AS A
TENANT-IN-COMMON, OR AS COMMUNITY PROPERTY, THE CO-OWNER OR JOINT SUBSCRIBER MUST SIGN HERE: 
  

	
	  

	
	  

	 (Print Name Here)

 Accepted as of
                    , 2006 
  

			
	ALCiS Health, Inc.
		
	By	 	  

		 	Mark Lemma, CFO

 IN WITNESS WHEREOF, the undersigned has executed this Subscription Agreement as of the date indicated
below. 
  

			
	CORPORATE SUBSCRIBERS:
	
	Dated:                     , 2006

  

					
		 	  

		 	(Name of Corporation)
			
		 	By:	 	  

		
		 	  

		 	(Print Name Here)
			
		 	Its:	 	  

		 	(Print Capacity Here)
			
	AND	 	By:	 	  

		
		 	  

		 	(Print Name Here)
			
		 	Its:	 	  

		 	(Print Capacity Here)

 Accepted as of
                    , 2006 
  

			
	ALCiS Health, Inc.
		
	By	 	  

		 	Mark Lemma, CFO

 IN WITNESS WHEREOF, the undersigned has executed this Subscription Agreement as of the date indicated
below. 
 OTHER ENTITY SUBSCRIBERS: 
 Dated:
                    , 2006 
  

			
	  

	(Name of Entity)
		
	By:	 	  

	
	  

	(Print Name Here)
		
	Its:	 	  

	(Print Capacity Here)

 Accepted as of
                    , 2006 
  

			
	ALCiS Health, Inc.
		
	By	 	  

		 	Mark Lemma, CFO

	
	STATE OF                                    
                      )
	                                       
                                      ) ss:
	COUNTY OF                                    
                  )

 On this      day of
                    , 2006, before me, the undersigned Notary Public, personally appeared/ is known to me (or satisfactorily proven to me) to
be the person whose name is subscribed to within the foregoing instrument and who acknowledged to me that he executed the same for the purposes therein contained. 
  

	
	  

	 Notary Public

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]